← Back to Screener
Bright Minds Biosciences Inc. Common Stock (DRUG)
Price$88.65
Favorite Metrics
Price vs S&P 500 (26W)76.22%
Price vs S&P 500 (4W)20.42%
Market Capitalization$876.58M
All Metrics
Book Value / Share (Quarterly)$8.36
P/TBV (Annual)5.45x
Cash Flow / Share (Quarterly)$-1.22
Price vs S&P 500 (YTD)9.30%
EPS (TTM)$-1.99
10-Day Avg Trading Volume0.00M
EPS Excl Extra (TTM)$-1.99
EPS (Annual)$-1.30
ROI (Annual)-14.88%
Cash / Share (Quarterly)$8.34
ROA (Last FY)-14.49%
EBITD / Share (TTM)$-1.94
ROE (5Y Avg)-69.97%
Cash Flow / Share (Annual)$-0.83
P/B Ratio13.46x
P/B Ratio (Quarterly)9.36x
Net Interest Coverage (TTM)-1324.94x
ROA (TTM)-27.92%
EPS Incl Extra (Annual)$-1.30
Current Ratio (Annual)36.10x
Quick Ratio (Quarterly)56.59x
3-Month Avg Trading Volume0.00M
52-Week Price Return-74.81%
Tangible BV / Share (Quarterly)$2.19
52-Week High$170.00
EPS Excl Extra (Annual)$-1.30
26-Week Price Return80.21%
Quick Ratio (Annual)35.68x
13-Week Price Return-6.21%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)57.37x
Enterprise Value$811.699
Cash / Share (Annual)$7.92
3-Month Return Std Dev65.21%
ROE (Last FY)-14.91%
Net Interest Coverage (Annual)-3.45x
EPS Basic Excl Extra (Annual)$-1.30
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.99
ROI (TTM)-28.41%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$5.98
Price vs S&P 500 (52W)-74.37%
Year-to-Date Return10.48%
5-Day Price Return2.62%
EPS Normalized (Annual)$-1.30
ROA (5Y Avg)-50.83%
Month-to-Date Return20.35%
Cash Flow / Share (TTM)$-1.83
EBITD / Share (Annual)$-1.47
LT Debt / Equity (Annual)0.68x
ROI (5Y Avg)-69.75%
LT Debt / Equity (Quarterly)0.18x
EPS Basic Excl Extra (TTM)$-1.99
P/TBV (Quarterly)1.99x
P/B Ratio (Annual)7.29x
Book Value / Share (Annual)$7.84
Price vs S&P 500 (13W)-6.90%
Beta1.89x
Revenue / Share (TTM)$0.00
ROE (TTM)-28.46%
52-Week Low$33.01
Analyst Recommendations
Jul 2022
Aug 2022
Sep 2022
Oct 2022
4.29
4.29
4.29
4.29
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
DRUGBright Minds Biosciences Inc. Common Stock | — | — | — | — | $88.65 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Bright Minds Biosciences develops next-generation serotonin agonists targeting treatment-resistant neuropsychiatric and pain disorders, including depression, PTSD, epilepsy, and chronic pain. The company's approach combines the therapeutic benefits of psychedelic and serotonergic compounds while reducing side effects compared to first-generation treatments. By addressing underlying neurocircuit abnormalities, Bright Minds targets large patient populations with significant unmet medical needs.